References
- IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Vol 100, A Review of Human Carcinogens. Part B: Biological Agents. Lyon, France: International Agency for Research on Cancer; 2011. International Agency for Research on Cancer. 2013.
- Orozco JJ, Carter JJ, Koutsky LA, Galloway DA. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol 2005; 79:9503 - 14; http://dx.doi.org/10.1128/JVI.79.15.9503-9514.2005; PMID: 16014913
- Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174 - 84; http://dx.doi.org/10.1006/viro.1996.0466; PMID: 8806551
- Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80:4664 - 72; http://dx.doi.org/10.1128/JVI.80.10.4664-4672.2006; PMID: 16641259
- Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12:959 - 69; PMID: 16085914
- Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108 - 15; PMID: 12522048
- de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17 - 27; http://dx.doi.org/10.1016/j.virol.2004.03.033; PMID: 15183049
- Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224:477 - 86; http://dx.doi.org/10.1006/viro.1996.0554; PMID: 8874508
- Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678 - 81; PMID: 2170694
- Brown MJ, Seitx H, Towne V, Muller M, Finnefrock AC. Development of neutralizing monoclonal antibodies for oncogenic HPV types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 2014; 21:587 - 93; http://dx.doi.org/10.1128/CVI.00773-13; PMID: 24574536
- Tan CY, Iglewicz B. Measurement-methods comparisions and linear statistical relationship. Technometrics 1999; 41:192 - 201; http://dx.doi.org/10.1080/00401706.1999.10485668
- Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, Mortel R. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature 1985; 317:639 - 41; http://dx.doi.org/10.1038/317639a0; PMID: 2997616
- Bryan JT, Jansen KU, Lowe RS, Fife KH, McClowry T, Glass D, Brown DR. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 1997; 53:185 - 8; http://dx.doi.org/10.1002/(SICI)1096-9071(199711)53:3<185::AID-JMV1>3.0.CO;2-4; PMID: 9365880
- Concepcion N, Frasch CE. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998; 5:199 - 204; PMID: 9521143
- Joura E. Efficacy and Immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. EUROGIN 2013, November 3-6.Available at http://www.eurogin.com/2013/index.php/abstracts/eurogin-2013-abstracts. 2014.
- Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7:38; http://dx.doi.org/10.1186/1750-9378-7-38; PMID: 23273245